Kyverna Therapeutics

Update in progress

KYTX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Kyverna Therapeutics, Inc. is a late-stage company developing CAR T-cell therapies for autoimmune diseases. Its lead KYV-101 is an autologous CD19 CAR T for stiff person syndrome, myasthenia gravis, and related autoimmune conditions. KYV-102 targets rapid whole-blood manufacturing of autologous CD19 CAR T cells, and KYV-201 is an allogeneic CD19 CAR T product. It collaborates with Intellia on allogeneic CAR therapy. Formerly BAIT Therapeutics, renamed in 2019. Founded 2018, based in Emeryville, California.

Company score

Sentiment: 0.48; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.46; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.15; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.32; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive